13F Data
13F filer · CIK 1263508

BAKER BROS. ADVISORS LP

NEW YORK, NY · filing since Q2 2013 · last filing Aug 14, 2026
Reported value
$20.0B
+$2.5B vs prior
Positions
84
New / sold out
9 / 9
Added / reduced
16 / 7
Turnover
2.9%
buys $827.7M · sells $541.6M
Top-10 weight
72.8%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
AddedRevolution Medicines, Inc.+1,888,000+19.8%+$353.6M
AddedInsmed Incorporated+1,375,000+18.5%+$146.6M
NewCelcuity Inc.+30,750,000–+$69.2M
AddedIDEAYA Biosciences, Inc.+1,063,515+26.9%+$39.6M
NewFaeth Therapeutics, Inc.+1,286,411–+$32.2M
AddedRelay Therapeutics, Inc.+1,666,666+143.7%+$31.2M
AddedAbCellera Biologics Inc.+2,736,200+9.0%+$21.5M
AddedCelldex Therapeutics, Inc.+517,241+77.7%+$19.2M
NewCytokinetics, Incorporated+211,267–+$18.0M
NewIntellia Therapeutics, Inc.+930,232–+$15.7M
15 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
ReducedEdgewise Therapeutics, Inc.-2,874,221-43.7%$-116.8M
Sold outAbivax S.A.-875,796-100.0%$-97.5M
Sold outCelcuity Inc.-30,750,000-100.0%$-74.9M
ReducedSummit Therapeutics Inc.-3,604,715-9.9%$-52.5M
Sold outSpyre Therapeutics, Inc.-1,000,000-100.0%$-50.4M
Sold outCentessa Pharmaceuticals plc-670,751-100.0%$-26.6M
Sold outImmunocore Holdings plc-734,397-100.0%$-22.1M
Sold outContineum Therapeutics, Inc.-1,420,838-100.0%$-18.6M
Sold outargenx SE-25,174-100.0%$-18.4M
ReducedImmatics N.V.-1,408,128-12.9%$-14.3M
6 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q2 2013: $5.1BQ3 2013: $7.0BQ4 2013: $7.1BQ1 2014: $7.9BQ2 2014: $8.2BQ3 2014: $7.9BQ4 2014: $9.8BQ1 2015: $12.0BQ2 2015: $11.4BQ3 2015: $10.8BQ4 2015: $12.1BQ1 2016: $9.5BQ2 2016: $9.5BQ3 2016: $11.0BQ4 2016: $10.2BQ1 2017: $12.2BQ2 2017: $11.4BQ3 2017: $12.3BQ4 2017: $11.5BQ1 2018: $11.8BQ2 2018: $13.3BQ3 2018: $15.2BQ4 2018: $12.2BQ1 2019: $15.6BQ2 2019: $14.7BQ3 2019: $14.7BQ4 2019: $18.8BQ1 2020: $16.2BQ2 2020: $22.7BQ3 2020: $25.0BQ4 2020: $26.5BQ1 2021: $23.1BQ2 2021: $22.8BQ3 2021: $22.8BQ4 2021: $20.6BQ1 2022: $17.4BQ2 2022: $17.6BQ3 2022: $15.3BQ4 2022: $16.7BQ1 2023: $18.4BQ2 2023: $17.3BQ3 2023: $17.4BQ4 2023: $8.8BQ1 2024: $8.0BQ2 2024: $7.8BQ3 2024: $9.6BQ4 2024: $9.4BQ1 2025: $9.0BQ2 2025: $10.3BQ3 2025: $13.8BQ4 2025: $17.1BQ1 2026: $17.4BQ2 2026: $20.0B
Q2 2013Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1Incyte CorporationCOM30,762,330$3.5B17.48%
2BeOne Medicines Ltd.SPONSORED ADS8,801,567$2.5B12.57%
3Revolution Medicines, Inc.COM11,443,357$2.1B10.74%
4Madrigal Pharmaceuticals, Inc.COM2,143,131$1.2B5.77%
5ACADIA Pharmaceuticals Inc.COM42,912,904$1.1B5.44%
6Kymera Therapeutics, Inc.COM8,657,242$992.7M4.97%
7Insmed IncorporatedCOM PAR $.018,796,111$937.8M4.70%
8Celcuity Inc.COM7,915,792$828.2M4.15%
9Kodiak Sciences Inc.COM19,919,186$776.1M3.89%
10Rhythm Pharmaceuticals, Inc.COM5,604,483$622.3M3.12%
74 more rows. Subscribe for $29/month to see every row, download the data and use the API.